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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To evaluate the effectiveness and safety of patient- or parent-initiated oral steroids for adults and children with asthma exacerbations.
B A C K G R O U N D
Description of the condition
Asthma is a chronic condition of the airways affecting an estimated
334 million people worldwide (Global Asthma Report 2014). Di-
rect treatment costs and indirect costs associated with lost pro-
ductivity are substantial and are among the highest for non-com-
municable diseases (Global Asthma Report 2014). Asthma trig-
gers may be allergic or non-allergic, resulting in airway inflamma-
tion, bronchoconstriction and limitation/obstruction of airflow.
During a worsening of asthma symptoms (i.e. an exacerbation),
which include tightness of the chest, wheeze and breathlessness,
patients will typically exhibit reduced lung function (BTS/SIGN
2014). Impairment of lung function can be reversed with treat-
ment and may return to normal. From a patient perspective, the
goals of asthma treatment are to prevent exacerbations, achieve
control of daytime and nocturnal symptoms, and permit nor-
mal exercise and functional capacity (GINA 2015). Treatment of
asthma should be guided by a personalised asthma action plan
(GINA 2015), and includes the avoidance of potential triggers,
the use of inhaled corticosteroids (ICS) and leukotriene recep-
tor antagonists to reduce airway inflammation, and the use of in-
haled long-acting beta2-agonists (LABA), short-acting beta2-ago-
nists (SABA) and anti-cholinergic bronchodilators (i.e. long-act-
ing muscarinic antagonists (LAMAs)) to relieve airflow limitation
(NICE 2007; NICE 2013; BTS/SIGN 2014; GINA 2015). Dur-
ing severe exacerbations, patients may need to attend a medical
centre or hospital emergency department for treatment with sys-
temic corticosteroids, which can be administered intravenously or
orally (BTS/SIGN 2014; GINA 2015). Some people with asthma
are prescribed oral corticosteroids (OCS) for self-administration
(i.e. patient-initiated) or to administer to their child with asthma
(i.e. parent-initiated), in the event of an exacerbation (Vuillermin
2007).
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Description of the intervention
Prophylactic treatment with corticosteroids is commonly used in
patients with asthma to reduce and control airway inflammation
(BTS/SIGN2014;GINA2015). ICS are used in preference to sys-
temic corticosteroids because the inhaled dose is delivered directly
to the respiratory tract (i.e. drug target), lowering the propensity
for systemic side-effects. Adverse effects associated with the long-
term use of systemic steroids include: effects on bone density (e.g.
osteoporosis and increased risk of femur neck fractures), growth re-
tardation in children, a tendency to hyperglycaemia, and suppres-
sion of the response to infection or injury (Rang 2015). Recurrent
short courses of prednisolone may also be associated with adverse
events, in particular, with a reduction of bone mineral accrual as
reported among participants in the Childhood Asthma Manage-
ment Program (CAMP) trial (CAMP research group 2000; Kelly
2008). However, evidence supports the short-term use of systemic
corticosteroids during acute asthma exacerbations (Rowe 2007;
Fernandes 2014). Patients remain particularly prone to repeat ex-
acerbations in the period immediately after an asthma exacerba-
tion and the use of systemic steroids can reduce the risk of a relapse
and the need for reliever inhalers, without major adverse effects
(Rowe 2007). Prescription of a ’rescue-pack’ (containing a course
of OCS) to a patient or their carer permits self-administered treat-
ment in the event of an exacerbation, as guided by a patient’s per-
sonalised asthma action plan (BTS/SIGN 2014).
How the intervention might work
Patient-initiated oral steroids may feature as part of a written
asthma action plan (GINA 2015), which should state when and
how to initiate treatment with OCS, and when to access medical
care if symptoms fail to respond to treatment. Compared with
OCS administered by an emergency department physician, pa-
tient- or parent-initiated treatment permits early administration
of systemic corticosteroids following the onset of an acute exacer-
bation. The benefits of OCS have been demonstrated within three
hours of administration, and delayed dosing of OCS is less effec-
tive at resolving acute asthma (Streetman 2002). Indeed, there is
some evidence from studies in children that early administration
of systemic steroids during an exacerbation can reduce asthma
symptoms and the number of days of missed school, compared
with physician-initiated steroids (Vuillermin 2010).
Why it is important to do this review
The use of patient-initiated oral steroids is common practice in
chronic obstructive pulmonary disease (COPD) (DoH 2010) and
the appropriate use of rescue packs is currently included in a Na-
tional Institute for Health and Care Excellence (NICE) quality
statement for managing COPD (NICE 2010). In line with their
use in COPD, the use of patient- and parent-initiated OCS for
asthma appears to be increasingly common in clinical practice
(Vuillermin 2007; BTS/SIGN 2014). For example, in an Aus-
tralian survey of 252 doctors involved in the care of children
with asthma, 85% of doctors reported recommending parent-ini-
tiated OCS to parents of children with asthma (Vuillermin 2007).
Additionally, BTS/SIGN guidelines on personalised action plan
content recommend coverage on starting oral steroids, “which
may include provision of an emergency course of steroid tablets”
(BTS/SIGN 2014). However, to date there is limited evidence for
the use of patient- or parent-initiated OCS for treating asthma ex-
acerbations (NACA 2015). An earlier Cochrane review evaluated
the evidence around parent-initiated oral corticosteroid therapy
for intermittent wheezing illnesses in children (Vuillermin 2006).
We will not consider pre-school wheeze in the present review.
It is important to consider the potential benefits of earlier treat-
ment with OCS against potential harms, which include the poten-
tial safety issues around delaying access to medical care whenOCS
are taken at home. Furthermore, the provision of rescue packs to
patients with asthma or to their carers will likely increase over-
all administration of oral corticosteroids; this has implications for
the incidence of steroid-associated side-effects, particularly in chil-
dren. Taken together, this information highlights the importance
of synthesising the evidence to establish whether this intervention
is safe and effective in people with asthma.
O B J E C T I V E S
To evaluate the effectiveness and safety of patient- or parent-ini-
tiated oral steroids for adults and children with asthma exacerba-
tions.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs). We will in-
clude studies reported as full-text, those published as abstract only,
and unpublished data. We will exclude cross-over trials because
the effects of oral corticosteroids can persist for a number of weeks
or months (Haahtela 1994) and it is unlikely that studies will
employ a sufficient washout period between treatment periods to
eliminate cross-over effects.
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Types of participants
We will include adults (aged ≥ 18 years) and children of school
age or older (i.e. aged ≥ 5 years) with a diagnosis of asthma.
Adults and children will be considered in separate comparisons.
Pre-school wheeze will not be considered by this review and as such
we will exclude studies of pre-school children. The diagnosis of
asthma should be determined by a clinician according to validated
national or international guidelines. We will exclude participants
with any respiratory co-morbidities (e.g. bronchiectasis, COPD).
If a study contains both adults and children, we will contact the
study authors to check if disaggregated data are available; if we are
unable to source these data we will use the average age (≥ 18 years)
of study participants to determine suitability for inclusion. Where
the average age of study participants is less than 18 years, we will
perform a sensitivity analysis to examine the effect of including
or excluding these studies. Finally, if a study includes children of
both school and pre-school age, we will exclude the study if the
average age is less than five years old.
Types of interventions
Wewill include studies comparing any patient- or parent-initiated
oral corticosteroid (OCS), with either placebo, normal care, an
alternative active treatment plan (e.g. doubling the dose of inhaled
steroids) or an identical personalised asthma exacerbationmanage-
ment plan without patient- or parent-initiated OCS. OCS (any
dose or duration) can be combined with other measures for the
management of an exacerbation (e.g. personalised asthma action
plan, increased use of reliever inhaler) provided that the measure
is not part of the randomised treatment. We will perform separate
comparisons for each type of comparator (e.g. patient-initiated
steroids versus placebo; patient-initiated steroids versus normal
care, etc); we will also perform separate comparisons for adults
and children. We define normal care as any measure that the pa-
tient would usually take to manage an exacerbation (e.g. increase
reliever inhaler use, seek medical advice, etc). We will also include
studies where the comparator group comprises a combination of
the above (e.g. personalised asthma action plan plus placebo).
Types of outcome measures
Primary outcomes
1. Hospital admissions for asthma
2. Asthma symptoms at follow-up (measured on a validated
scale e.g. Asthma Control Questionnaire (ACQ))
3. Serious adverse events
We selected the primary outcomes to represent an important mea-
sure of resource use, a patient-reported outcome, and safety.
Secondary outcomes
1. Unscheduled visit to healthcare provider (e.g. accident and
emergency, general practitioner)
2. New exacerbation in follow-up period
3. Asthma control at follow-up
4. Reliever medication use
5. Days off school (children) or study/work (adults) lost
6. Time to full resolution of symptoms
7. Adverse events
Reporting one or more of the outcomes listed here in the study
is not an inclusion criterion for the review. If a study uses more
than one scale to report the same outcome, or if different scales
are used across studies, we will analyse the different scales together
using the standardised mean difference (SMD).
Search methods for identification of studies
Electronic searches
We will identify trials from the Cochrane Airways Group’s Spe-
cialised Register (CAGR), which is maintained by the Informa-
tion Specialist for the Group. The Register contains trial reports
identified through systematic searches of bibliographic databases
including the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, EMBASE, CINAHL, AMED, and
PsycINFO, and handsearching of respiratory journals and meet-
ing abstracts (see Appendix 1 for further details). We will search
all records in the CAGR using the search strategy in Appendix 2.
We will also conduct a search of
ClinicalTrials.gov (www.ClinicalTrials.gov) and the WHO trials
portal (www.who.int/ictrp/en/). We will search all databases from
their inception to the present, and we will impose no restriction
on language of publication.
Searching other resources
We will check reference lists of all primary studies and review ar-
ticles for additional references. We will search relevant manufac-
turers’ websites for trial information.
We will search for errata or retractions from included studies pub-
lished in full-text on PubMed (www.ncbi.nlm.nih.gov/pubmed)
and report the date this was done within the review.
Data collection and analysis
Selection of studies
Two review authors (MBG, DE) will independently screen titles
and abstracts of all the potentially-relevant studies we identify as
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a result of the search and code them as ’retrieve’ (eligible or po-
tentially eligible/unclear) or ’do not retrieve’. We will retrieve the
full-text study reports/publication and two review authors (MBG,
DE) will independently screen the full-text and identify studies
for inclusion, and identify and record reasons for exclusion of the
ineligible studies. We will resolve any disagreement through dis-
cussion or, if required, wewill consult a third review author (MM).
We will identify and exclude duplicates and collate multiple re-
ports of the same study, so that each study rather than each report
is the unit of interest in the review. We will record the selection
process in sufficient detail to complete a PRISMA flow diagram
and ’Characteristics of excluded studies’ table (Moher 2009).
Data extraction and management
We will use a data collection form for study characteristics and
outcome data, which has been piloted on at least one study in
the review. Two review authors (MBG, DE) will extract study
characteristics from included studies. We will extract the following
study characteristics.
1. Methods: study design, total duration of study, details of
any ’run in’ period, number of study centres and location, study
setting, withdrawals, and date of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria, and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
Two review authors (MBG, DE) will independently extract out-
come data from the included studies. We will note in the ’Char-
acteristics of included studies’ table if outcome data were not re-
ported in a usable way. We will resolve disagreements by consen-
sus or by involving a third review author (MM). One review au-
thor (DE) will transfer data into the Review Manager (RevMan
2014) file.We will double-check that data are entered correctly by
comparing the data presented in the systematic review with the
study reports. A second review author (DE) will spot-check study
characteristics for accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (MBG, DE) will independently assess risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve any disagreements by discussion or by involving
another review author (MM). We will assess the risk of bias ac-
cording to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We will grade each potential source of bias as high, low or unclear
risk, and provide a quote from the study report together with a
justification for our judgment in the ’Risk of bias’ table. We will
summarise the ’Risk of bias’ judgements across different studies for
each of the domains listed.Wewill consider blinding separately for
different key outcomes where necessary (e.g. for unblinded out-
come assessment, risk of bias for all-cause mortality may be very
different than for a patient-reported pain scale). Where informa-
tion on risk of bias relates to unpublished data or correspondence
with a trialist, we will note this in the ’Risk of bias’ table.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
Assesment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and report any deviations from it in the ’Differences between pro-
tocol and review’ section of the systematic review.
Measures of treatment effect
We will analyse dichotomous data as odds ratios (OR) and con-
tinuous data as mean difference or standardised mean difference
(SMD). We will enter data presented as a scale with a consistent
direction of effect.
Wewill undertakemeta-analyses only where this ismeaningful, i.e.
if the treatments, participants and the underlying clinical question
are similar enough for pooling to make sense.
We will narratively describe skewed data reported as medians and
interquartile ranges.
Where multiple trial arms are reported in a single trial, we will
include only the relevant arms. If two comparisons (e.g. drug A
versus placebo and drug B versus placebo) are combined in the
same meta-analysis, we will halve the control group to avoid dou-
ble-counting.
Unit of analysis issues
For dichotomous outcomes, we will report participants, rather
than events, as the unit of analysis. For example, for the primary
outcome ’unscheduled visits to the healthcare provider’ we would
record the number of participantswith anunscheduled visit, rather
than the number of unscheduled visits per participant.
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Dealing with missing data
We will contact investigators or study sponsors in order to verify
key study characteristics and obtain missing numerical outcome
data where possible (e.g. when a study is identified as abstract
only). Where this is not possible, and the missing data are thought
to introduce serious bias, we will explore the impact of including
such studies in the overall assessment of results by conducting a
sensitivity analysis.
Assessment of heterogeneity
We will use the I² statistic to measure heterogeneity among the
studies in each analysis. If we identify substantial heterogeneity we
will report it and explore possible causes by prespecified subgroup
analysis.
Assessment of reporting biases
If we are able to pool more than 10 studies, we will create and
examine a funnel plot to explore possible small study and publi-
cation biases.
Data synthesis
We will use a random-effects model and perform a sensitivity
analysis with a fixed-effect model.
’Summary of findings’ table
We will create a ’Summary of findings’ table using the following
outcomes: hospital admissions for asthma; asthma symptoms at
follow up; serious adverse events; unscheduled visit to healthcare
provider; asthma control at follow-up, days off school or study/
work lost, adverse events. We will use the five GRADE consid-
erations (study limitations, consistency of effect, imprecision, in-
directness and publication bias) to assess the quality of a body
of evidence as it relates to the studies which contribute data to
the meta-analyses for the prespecified outcomes (Guyatt 2011).
We will use methods and recommendations described in Section
8.5 and Chapter 12 of the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011) using GRADEpro software
(GRADEpro GDT). We will justify all decisions to down- or up-
grade the quality of studies using footnotes and we will make com-
ments to aid the reader’s understanding of the review where nec-
essary.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses.
1. Baseline asthma severity (stratified by background
medication)
We will use the following outcomes in subgroup analyses.
1. Hospital admissions for asthma
2. Asthma symptoms at follow-up
3. Serious adverse events
We will use the formal test for subgroup interactions in Review
Manager (RevMan 2014).
Sensitivity analysis
If necessary, we plan to carry out the following sensitivity analyses
to explore the effect of including/excluding:
1. Studies that include both adults and children/adolescents,
where the average age of participants is < 18 years
2. Unpublished data (i.e. no peer-reviewed full-text paper
available)
3. Studies at high risk of performance or detection bias
4. Studies at high risk of any other bias
5. Studies with missing data
A C K N OW L E D G E M E N T S
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group’s Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL (Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
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Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
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8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
Appendix 2. Search strategy to identify relevant trials from the CAGR
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 prednis*
#6 methylprednis*
#7 dexamethasone
#8 cortisone
#9 hydrocortisone*
#10 medrol
#11 solumedrol
#12 solu-medrol
#13 betamethasone
#14 triamcinolone
#15 (oral* or systemic*) near3 (steroid* or corticosteroid* or glucocorticoid*)
#16 OCS:ti,ab
#17 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16
#18 MeSH DESCRIPTOR Patient Participation
#19 MeSH DESCRIPTOR Decision Making
#20 (patient* or parent* or caregiver* or carer*)NEAR (initiat* or suggest* or instigat* or originat* or request* or propose* or encourage*
or advocate*)
#21 self-refer* or self NEXT refer*
#22 #18 or #19 or #20 or #21
#23 #4 AND #17 AND #22
#24 (#23) AND (INREGISTER)
[Note: in search line #1, MISC1 denotes the field in the record where the reference has been coded for condition, in this case, asthma]
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